CD19 and neoplasm: Therefore, to overcome the antigen loss as a resistance mechanism in immunotherapy, CAR constructs that target multiple antigens including CD19 are designed to resolve the inherent tumor heterogeneity and thus decrease the relapse rate of cancer.